Paper Details

  1. Home
  2. Paper Details

Novel dual endothelin receptor antagonist macitentan reverses severe pulmonary arterial hypertension in rats.

Author: AbeKohtaro, HiranoKatsuya, HirookaYoshitaka, Kunita-TakanezawaMutsumi, KuwabaraYukimitsu, OkaMasahiko, SunagawaKenji

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Macitentan, a dual endothelin receptor antagonist, was evaluated in a preclinical model of severe pulmonary arterial hypertension (PAH). Macitentan effectively reversed the high right ventricular systolic pressure, improved cardiac output, and reduced the development of right ventricular hypertrophy, luminal occlusive lesions, and medial wall thickening. Importantly, macitentan did not increase serum liver enzyme levels, suggesting it may be a safer option than bosentan for treating severe PAH.
Paper Details　
Original Abstract of the Article :
The efficacy of endothelin (ET) receptor antagonist bosentan in patients with severe pulmonary arterial hypertension (PAH) remains limited, partly because its higher doses for potential blockade of ET receptors have never been tested due to liver dysfunction. We hypothesized that rigorous blockade o...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1097/FJC.0000000000000141

データ提供：米国国立医学図書館（NLM）

A New Oasis for Pulmonary Arterial Hypertension: The Potential of Macitentan

Pulmonary arterial hypertension (PAH) is a serious and often life-threatening condition. It's like a desert sandstorm, constricting blood vessels in the lungs and making it difficult for the heart to pump blood effectively. This study investigates the potential of macitentan, a novel dual endothelin receptor antagonist, as a treatment for severe PAH.

The authors conducted preclinical studies using a rat model of severe PAH. The results demonstrated that macitentan effectively reversed PAH, reducing right ventricular systolic pressure, improving cardiac output, and mitigating the development of heart and lung damage.

A New Hope for PAH: Macitentan Offers a Potential Treatment Option

This study presents promising evidence for the potential of macitentan as a treatment for severe PAH. The drug's ability to reverse PAH symptoms and improve heart and lung function offers hope for individuals struggling with this challenging condition.

Navigating the Desert of PAH: Exploring New Treatment Strategies for a Complex Disease

This research highlights the ongoing search for effective treatments for PAH. The discovery of macitentan as a potential therapeutic agent opens up new avenues for managing this complex and life-threatening condition.

Dr. Camel's Conclusion

This study presents a promising new direction for PAH treatment. The findings suggest that macitentan may offer a valuable tool for managing this challenging condition. As a researcher, I am eager to see further studies explore the efficacy and safety of this drug in human clinical trials. The potential of macitentan to improve the lives of individuals with PAH is a testament to the ongoing progress in medical research and the quest for effective therapies.

Date :
  1. Date Completed 2015-07-13
  2. Date Revised 2014-11-08
Further Info :

Pubmed ID

25084082

DOI: Digital Object Identifier

10.1097/FJC.0000000000000141

Related Literature

Article Analysis
・Side Effects of macitentan
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.